Nektar Therapeutics NKTR
35.91 USD -0.53 (-1.45%)
Regular-session close
38.75 +2.84 +7.91%
Pre-market · Nov 18, 7:13 AM ET
35.42 Day range 36.47
33.40 52-week range 109.00
- YTD
- -15.07%
- 1 year
- -39.73%
News
seekingalpha.com Nektar Therapeutics (NKTR) Presents at UBS Global Biopharma Conference 2026 Transcript Nektar Therapeutics ( NKTR ) UBS Global Biopharma Conference 2026 November 17, 2026 6:20 AM EST Company Participants Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Conference…benzinga.com Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149 Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.
zacks.com NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.
seekingalpha.com Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
marketbeat.com What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call Nektar Therapeutics NASDAQ: NKTR said it has initiated three Phase III studies of its experimental drug rezpegaldesleukin, or REZPEG, in atopic dermatitis and expects to begin a pivotal alopecia…
zacks.com Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to a loss of $1.85 per share a year ago.benzinga.com Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(2.08) by 21.63 percent. This is a 12.83 percent increase over losses of…
prnewswire.com Nektar Therapeutics Announces Third Quarter 2026 Financial Results SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.…
prnewswire.com Nektar Therapeutics to Participate in Two Investor Conferences in November SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global…
